(19)
(11) EP 1 687 329 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.03.2010 Bulletin 2010/11

(45) Mention of the grant of the patent:
23.12.2009 Bulletin 2009/52

(21) Application number: 04810619.9

(22) Date of filing: 10.11.2004
(51) International Patent Classification (IPC): 
C12N 15/37(2006.01)
A61K 39/12(2006.01)
C07K 14/025(2006.01)
 C12N 15/81(2006.01)
A61K 48/00(2006.01)
(86) International application number:
PCT/US2004/037372
(87) International publication number:
WO 2005/047315 (26.05.2005 Gazette 2005/21)

(54)

OPTIMIZED EXPRESSION OF HPV 58 L1 IN YEAST

OPTIMIERTE EXPRESSION VON HPV-58-L1 IN HEFE

EXPRESSION OPTIMISEE DE HPV 58 L1 DANS DE LA LEVURE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
LT LV

(30) Priority: 12.11.2003 US 519211 P

(43) Date of publication of application:
09.08.2006 Bulletin 2006/32

(73) Proprietor: Merck Sharp & Dohme Corp.
Rahway, NJ 07065 (US)

(72) Inventors:
  • BRYAN, Janine, T.
    Rahway, New Jersey 07065-0907 (US)
  • BROWNLOW, Michelle, K.
    Rahway, New Jersey 07065-0907 (US)
  • SCHULTZ, Loren, D.
    Rahway, New Jersey 07065-0907 (US)
  • WANG, Xin-Min
    Rahway, New Jersey 07065-0907 (US)
  • JANSEN, Kathrin, U.
    Rahway, New Jersey 07065-0907 (US)

(74) Representative: Buchan, Gavin MacNicol et al
Merck Sharp & Dohme Limited European Patent Department Hertford Road
Hoddesdon Hertfordshire EN11 9BU
Hoddesdon Hertfordshire EN11 9BU (GB)


(56) References cited: : 
WO-A-01/14416
 WO-A-2004/084831
   
  • TOBERY T W ET AL: "Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 13-14, 28 March 2003 (2003-03-28), pages 1539-1547, XP004412501 ISSN: 0264-410X
  • ZHOU JIAN ET AL: "Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 6, June 1999 (1999-06), pages 4972-4982, XP002164427 ISSN: 0022-538X
  • LIU W J ET AL: "Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 5-6, 12 December 2001 (2001-12-12), pages 862-869, XP004312531 ISSN: 0264-410X
  • SCHILLER J T ET AL: "PAPILLOMAVIRUS-LIKE PARTICLE VACCINES" NATIONAL CANCER INSTITUTE. MONOGRAPHS, US NATIONAL CANCER INSTITUTE, BETHESDA, MD, US, vol. 28, 2000, pages 50-54, XP008016223 ISSN: 0083-1921
  • HOFMANN K J ET AL: "Sequence dertermination of human papillomavirus type 6a and assembly of virus like particles in Saccharomyces cerevisiae" VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 209, 1995, pages 506-518, XP002100680 ISSN: 0042-6822
  • JANSEN K U ET AL: "Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 16, November 1995 (1995-11), pages 1509-1514, XP004057408 ISSN: 0264-410X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).